Pre-clinical biodistribution studies confirmed the tumour-specific targeting of FGFR2-TTC, which also demonstrated promising pre-clinical efficacy in FGFR2-amplified xenograft models including SNU-16 GC cells [120]. Here, FGFR2 is linked to neoplasm.